本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）分别于 2025 年 4 月 18 日召开 第十一届董事会第二次（临时）会议、2025 年 5 月 6 日召开 2025 年第二次临时 股东会，审议通过了以本公司所持有的广发证券股份有限公司（股票代码：000776） A 股股票为标的非公开发行可交换公司债券的相关议案。具体内容详见公司于 2025 年 4 月 19 日披露的《辽宁成大股份有限公司关于拟非公开发行可交换公司 债券的公告》（公告编号：临 2025－035）。基于公司实际经营情况，公司经营 管理层根据股东会及董事会的授权对本次非公开发行可交换公司债券方案中的 发行规模进行调整，由不超过 50 亿元人民币调减为不超过 28 亿元人民币。 近日公司收到深圳证券交易所（以下简称"深交所"）出具的《关于辽宁成 大股份有限公司非公开发行可交换公司债券符合深交所挂牌条件的无异议函》 （深证函〔2025〕897 号）。根据《公司债券发行与交易管理办法》和《深圳证 券交易所非公开发行公司债券挂牌 ...

Group 1 - The company will hold its third extraordinary general meeting of shareholders on September 30, 2025, at 14:30 in the company meeting room [1][2] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's shareholder meeting online voting system [1][2] - The online voting period is set for September 30, 2025, with specific time slots for trading system voting and internet platform voting [1][4] Group 2 - There are no related shareholders required to abstain from voting [10] - All proposals for the meeting have been approved by the company's board of directors on August 29, 2025 [2] - Shareholders must complete voting on all proposals before submission [5] Group 3 - Shareholders registered by the close of trading on the registration date are entitled to attend the meeting and may appoint a proxy to vote on their behalf [6][11] - The registration process for shareholders includes specific documentation requirements for both natural and legal persons [9][11] - The registration period is from September 23, 2025, 9:00 to 17:00 [15]

辽宁成大股份有限公司 2025年第三次临时股东会 会议文件 辽宁成大股份有限公司 GD LIAONING CHENG DA CO., LTD. 2025年9月30日 中国 大连 辽宁成大股份有限公司 2025 年第三次临时股东会会议文件目录 | 2025 年第三次临时股东会会议议程 | | --- | | 一、关于修订《辽宁成大股份有限公司募集资金管理制度》的议案 | | 二、关于修订《辽宁成大股份有限公司董事及高级管理人员薪酬管理制度》的议 | | 家 | l 辽宁成大股份有限公司 2025 年第三次临时股东会会议议程 会议时间： 一、现场会议时间：2025 年 9 月 30 日 14：30 二、网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自 2025 年 9 月 30 日 至 2025 年 9 月 30 日 现场会议地点：公司会议室 现场会议主持人：董事长 徐飚先生 会议出席对象： 一、股权登记日收市后在中国证券登记结算有限责任公司上海分公司登记在 册的公司股东有权出席股东会（具体情况详见下表），并可以以书面形式委托代 理人出席会议和参加表决。该代 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025-069 辽宁成大股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第三次临时股东会 召开的日期时间：2025 年 9 月 30 日 14 点 30 分 召开地点：公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年9月30日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 30 日 至2025 年 9 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30 ...

Core Points - The China-ASEAN Regional Pharmaceutical Trading (Procurement) Platform has successfully completed its first cross-border online transaction and settlement, marking a significant milestone for Chinese pharmaceutical companies aiming to expand into ASEAN and SCO countries [1] Group 1 - The platform was officially launched in January 2025 and is the first cross-border regional pharmaceutical procurement platform guided by the National Medical Security Administration [1] - The transaction involved Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and a party from Singapore, demonstrating the platform's capability as a convenient and secure channel for international trade [1] - The establishment of this platform indicates its maturity in serving Chinese pharmaceutical enterprises in their overseas endeavors [1]

Core Viewpoint - The establishment of the China-ASEAN Regional Pharmaceutical Trading Platform marks a significant breakthrough in cross-border online transaction settlements for pharmaceutical companies, facilitating easier access for Chinese enterprises to ASEAN markets [1] Group 1: Platform Development - The platform is recognized as China's first cross-border regional pharmaceutical trading platform, successfully completing its first online cross-border transaction [1] - The platform serves as a "direct channel" for Chinese enterprises and procurement parties from ASEAN countries, providing comprehensive transaction services [1] Group 2: Company Participation - Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the first Chinese pharmaceutical company to complete a transaction through the platform, successfully supplying its product, Bailin capsules, to Singapore [1] - Currently, 114 leading Chinese pharmaceutical companies and 10 foreign pharmaceutical purchasers have joined the platform [1] Group 3: Future Prospects - The Guangxi Zhuang Autonomous Region aims to achieve breakthroughs in mutual recognition of pharmaceutical regulations with ASEAN countries through the platform [1] - The platform is expected to promote more "small and beautiful" pharmaceutical livelihood projects in the future [1]

Group 1 - The core point of the article is that Liaoning Chengda has seen a decrease in the number of shareholders and an increase in average shareholding quantity, while its average shareholding value remains below the industry average [1][2] - As of June 30, 2025, the number of shareholders for Liaoning Chengda is 66,011, a decrease of 3,580 or 5.14% from March 31, 2025 [1][2] - The average number of shares held per shareholder increased from 22,000 to 23,200, with an average shareholding value of 254,900 yuan [1][2] Group 2 - The stock price of Liaoning Chengda increased by 5.36% from March 31, 2025, to June 30, 2025, despite the decrease in the number of shareholders [1][2] - The average number of shareholders in the biopharmaceutical industry is 34,000, indicating that Liaoning Chengda's shareholder count is above the industry average [1] - During the same period, the net outflow of main funds was 237 million yuan, while retail investors saw a net inflow of 103 million yuan [2]

Core Viewpoint - Liaoning Chengda Co., Ltd. reported strong financial performance in the first half of 2025, with significant revenue and profit growth driven by its biopharmaceutical, financial investment, and trade sectors [1][2][3]. Financial Performance - In H1 2025, the company achieved operating revenue of 5.348 billion yuan and a net profit of 718 million yuan, marking a year-on-year increase of 56.18% [1]. - The financial investment segment, primarily from Guangfa Securities and China Insurance, generated investment income of 1.076 billion yuan and 86.3 million yuan, with year-on-year growth of 53.19% and 143.94%, respectively [7][8]. Biopharmaceutical Development - Chengda Biopharmaceutical achieved operating revenue of 707 million yuan and a net profit of 122 million yuan in H1 2025, with a 100% pass rate for vaccine product approvals [3]. - The company signed a cooperation agreement with a leading AI technology firm to establish an "AI + Vaccine R&D Joint Laboratory," enhancing its research capabilities [2]. Trade Sector Performance - The domestic and international trade segment reported operating revenue of 4.634 billion yuan, a year-on-year increase of 3.20%, and a net profit of 22.38 million yuan, up 40.52% [4]. - The company is focusing on strengthening team building, resource integration, and market opportunity capture in its trade operations [5]. Financial Strategy and Resource Optimization - The new management team has been actively optimizing the company's debt structure and financing capabilities, issuing short-term financing bonds at competitive rates [8]. - The company aims to enhance its core competitiveness and financial resilience through strategic resource allocation and financial tool utilization [8].

Group 1 - Company Liaoning Chengda announced that its subsidiary Xinjiang Baoming Mining has obtained mining licenses for oil shale in two areas, Wujiawan and Mutasi, in Xinjiang [1] - The company has confirmed the value of the mining rights based on resource value assessments, and will increase its investment in Xinjiang Baoming without additional cash input, maintaining a debt balance of 4.593 billion yuan after the capital increase [1] - Following the capital increase, the company's equity stake in Xinjiang Baoming will rise from 60.5% to 62%, while the profit-sharing ratio remains unchanged at 62% [1] Group 2 - For the year 2024, Liaoning Chengda's revenue composition is projected to be 84.87% from import and export trade, 14.85% from biopharmaceuticals, and 0.28% from other sources [2] - The current market capitalization of Liaoning Chengda is 20 billion yuan [3]

证券代码：600739 证券简称：辽宁成大 公告编号：2025－067 辽宁成大股份有限公司 第十一届董事会第六次会议决议公告 本议案已经公司董事会审计委员会审议通过。 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 二、关于修订《辽宁成大股份有限公司董事会秘书工作制度》的议案（详见 上海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 三、关于修订《辽宁成大股份有限公司内幕信息及知情人管理制度》的议案 （详见上海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 四、关于修订《辽宁成大股份有限公司担保业务管理制度》的议案（详见上 海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 19 日以 书面和电子邮件方式发出召开第十一届董事会第六次会议的通知，会议于 2025 年 8 月 29 日在公司会议室以通讯方式召开并 ...